PDCD1 and cholangiocarcinoma: As a novel class of immunotherapeutic agents, immune check point inhibitors targeting programmed cell death protein 1 (PD-1) have shown clinical efficacy in treating various tumors (7, 8), but their role in CCA remains in the exploratory stages, with ongoing clinical trials.